Menu Search
Equities

Revenio Group Oyj

0KFH:LSE

Revenio Group Oyj

Actions
  • Price (EUR)29.10
  • Today's Change-0.28 / -0.95%
  • Shares traded23.00
  • 1 Year change+20.53%
  • Beta--
Data delayed at least 20 minutes, as of Nov 14 2024 09:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Revenio Group Oyj, formerly Done Solutions Oyj, is a Finland-based company primarily engaged in the health technology segment. The Company’s activities are divided into two business areas: Revenio Health Tech, which is responsible for the design, manufacture and sale of tonometers and bone density measurement devices; as well as Revenio Technology and Services, which provides contact center services for material handling systems. It distributes products in a range of countries, including the United States, Canada, Australia, Japan and India. Furthermore, the Company is a parent of Done Medical Oy, Kauhajoen Sisalogistiikka Oy, Icare Finland Oy, Oscare Medical Oy and Midas Touch Oy, among others.

  • Revenue in EUR (TTM)102.08m
  • Net income in EUR19.01m
  • Incorporated2001
  • Employees230.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.